# Evaluation of Albumin and Midodrine Versus Albumin Alone in Outcome of Refractory Ascites in Patients With Decompensated Cirrhosis.

> **NCT04816240** · NA · UNKNOWN · sponsor: **Institute of Liver and Biliary Sciences, India** · enrollment: 200 (estimated)

## Conditions studied

- Liver Cirrhosis

## Interventions

- **DRUG:** Midodrine
- **BIOLOGICAL:** Albumin
- **OTHER:** Standard Medical Treatment
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT04816240
- **Lead sponsor:** Institute of Liver and Biliary Sciences, India
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-05-15
- **Primary completion:** 2022-03-19
- **Final completion:** 2022-03-19
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2021-06-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04816240

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04816240, "Evaluation of Albumin and Midodrine Versus Albumin Alone in Outcome of Refractory Ascites in Patients With Decompensated Cirrhosis.". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04816240. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*